Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials

TAGS

Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the 2023 American Society of Hematology (ASH) Annual Meeting. This trial, part of a global, multicenter Phase 2 study, evaluates the efficacy of Breyanzi (lisocabtagene maraleucel, liso-cel) in patients with relapsed or refractory follicular lymphoma (FL).

TRANSCEND FL: A Significant Study in Lymphoma Therapy

TRANSCEND FL is the largest clinical trial to date evaluating a CAR T cell therapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma, including FL. This high-risk, second-line cohort study presents the first data on the use of CAR T therapy in this patient group. Additionally, long-term data from the TRANSCEND CLL 004 study on Breyanzi in chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) were also presented.

See also  Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL

Breyanzi’s Impact in FL and CLL Treatment

According to Dr. Anne Kerber, senior vice president at Bristol Myers Squibb, Breyanzi continues to demonstrate a potential best-in-class profile in treating FL, offering clinically meaningful benefits and improved outcomes for patients with high unmet needs. The TRANSCEND clinical trials highlight Breyanzi’s significant role in advancing cell therapy treatments for patients with complex hematological conditions.

Bristol Myers Squibb Presents Pioneering Data on Breyanzi at ASH 2023, Revolutionizing Lymphoma Treatment

Bristol Myers Squibb Presents Pioneering Data on Breyanzi at ASH 2023, Revolutionizing Lymphoma Treatment

Key Findings and Patient Outcomes

In the TRANSCEND FL trial, Breyanzi showed impressive efficacy in patients with high-risk, relapsed or refractory FL, with nearly all patients achieving a complete response. The overall response rate (ORR) was 95.7%, with a median duration of response and progression-free survival not yet reached. This promising outcome emphasizes Breyanzi’s potential in providing lasting responses and manageable safety profiles for patients after the failure of front-line therapy.

See also  MEDiC Life Sciences, Bristol Myers Squibb to advance discovery of tumor targets

Patient-Reported Outcomes and Quality of Life

An exploratory analysis of patient-reported outcomes (PROs) from TRANSCEND FL also indicates significant improvements in quality of life, disease symptoms, and functioning for patients treated with Breyanzi. These improvements were more pronounced in patients treated in the second-line setting, highlighting the therapy’s effectiveness and patient-centric approach.

See also  Bristol Myers Squibb to acquire Mirati Therapeutics in $4.8bn deal

Ongoing Clinical Development

Bristol Myers Squibb’s clinical development program for Breyanzi includes studies in earlier lines of treatment for patients with relapsed or refractory large B-cell lymphoma (LBCL) and other types of lymphoma and leukemia. The company’s commitment to innovative treatments is further reinforced by these promising clinical results and ongoing studies.

The findings from the TRANSCEND FL and CLL 004 studies, presented at ASH 2023, mark a significant advancement in the field of hematology and oncology. Bristol Myers Squibb continues to lead in the development of innovative therapies, aiming to bring new hope and advanced treatment options to patients battling lymphoma and leukemia.

CATEGORIES
TAGS
Share This

COMMENTS

Wordpress (0)